Tradestie Institutional Equity Comparison Engine · Market Close Nov 17, 2026

ENTX vs LYRA: Which Stock Is the Better Buy Now?

Deterministic 6-pillar institutional evaluation across valuation multiples, TTM & multi-year operating margins, cash generation, options IV skew, and supply-chain moat.

ENTX Wins Head-to-Head Institutional Verdict (3–2 across 6 Pillars · 6–1 Matrix Metrics)

ENTX Overall Winner 6-Pillar Tally: ENTX 3 – 2 LYRA (1 Tie) Matrix Metrics: ENTX 6 – 1 LYRA

As of Nov 17, 2026, Entera Bio Ltd. (ENTX) is the stronger overall head-to-head candidate over Lyra Therapeutics, Inc. (LYRA) in the Tradestie Institutional Equity Comparison Engine, winning 6–1 core matrix metrics and 3–2 across our 6-pillar institutional scorecard (led by Profitability & Quality, Balance Sheet & Cash Flow, Options & Positioning). ENTX carries a Unified Composite Score of 53.5/100 (HOLD) at $3.01 (N/M Forward P/E, 0.0% operating margin), whereas LYRA carries 52.2/100 (HOLD) at $0.49 (N/M Forward P/E, -25032.0% operating margin).

  • Technical & Structure Timing Caution: ENTX trades in a Neutral technical trend (CONSOLIDATION options phase, RSI 49.8); meanwhile LYRA is in a short-term Weinstein Markdown pullback below its falling 50-day moving average (RSI 21.5). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.

Executive Snapshot Side-by-Side Composite Ratings & Technical Regime

Ask Alpha AI About ENTX vs LYRA
ENTX NASDAQ Head-to-Head Winner
Entera Bio Ltd. Ordinary Shares
Biological Products, (No Disgnostic Substances)
$3.01
-0.33% 1D
Market Cap $541.6M
TTM Revenue N/A
Forward P/E N/M
Beta / 30D Vol 1.07β · 45% Vol
Unified Composite Score
53.5 / 100 HOLD
Tech 35.0 Fund 55.0 Flow 72.0 Mom 60.0
Weinstein Technical Phase Neutral · Hold
Mixed signals - no dominant trend phase, RSI 50
RSI-14: 49.8 · SMA20: $3.09 · SMA50: $2.90
LYRA NASDAQ
Lyra Therapeutics, Inc. Common Stock
Surgical & Medical Instruments & Apparatus
$0.49
-62.5% 1D
Market Cap $2.3M
TTM Revenue $600,000
Forward P/E N/M
Beta / 30D Vol 0.33β · 248% Vol
Unified Composite Score
52.2 / 100 HOLD
Tech 60.0 Fund 56.0 Flow 50.0 Mom 59.0
Weinstein Technical Phase Markdown · Sell / avoid
Price below a falling SMA50 (slope -35.3%), weak momentum, RSI 21
RSI-14: 21.5 · SMA20: $1.27 · SMA50: $1.82

6-Pillar Scorecard Institutional Category Breakdown (ENTX 3 – 2 LYRA)

Columns: Metric · ENTX · LYRA
1. Valuation Multiples LYRA
Forward P/E N/M N/M
Trailing P/E N/M N/M
PEG Ratio N/M N/M
EV / Revenue N/M 3.9x
2. Growth & Scale LYRA
Revenue Growth (YoY) -100.0% -87.2%
Earnings Growth (YoY) +0.0% +0.0%
TTM Revenue (USD) N/A $600,000
Market Cap $541.6M $2.3M
3. Profitability & Quality ENTX
Gross Margin N/A N/A
Operating Margin 0.0% -25032.0%
Net Profit Margin 0.0% 0.0%
Return on Equity (ROE) -20.3% -404.5%
4. Balance Sheet & Cash Flow ENTX
Cash Generation (TTM) -$16M -$32M EBITDA
Cash Flow Margin N/A N/A
Net Cash / Leverage $265M Net Cash -404.5% ROE
Dividend Yield None (0.00%) None (0.00%)
5. Options & Positioning ENTX
Options Structure Phase CONSOLIDATION UNCLASSIFIED
Current IV / %ile 113.8% (32nd %ile) N/A (N/A)
Put/Call OI Skew N/A N/A
OBV Trend / Tech Phase NEUTRAL · Neutral NEUTRAL · Markdown
6. R&D & Supply-Chain Moat Tie
OpEx & R&D Intensity N/A N/A
90D R&D Disclosures 0 papers 0 papers
Competitive Moat Cyclical / Execution-Driven Positioning Cyclical / Execution-Driven Positioning
Supply-Chain Role Biotechnology Operator Biotechnology Operator

Core Matrix Head-to-Head Valuation, Margin, Cash Flow & Risk Table

Core Matrix Wins: ENTX (6) vs LYRA (1)
Institutional Metric ENTX LYRA Criterion Row Edge
Market Capitalization
Scale
$541.6M $2.3M Larger Scale ENTX
Trailing P/E Ratio
Valuation
N/M N/M Lower Multiple Tie
Forward P/E Ratio
Valuation
N/M N/M Lower Multiple Tie
Revenue Growth (YoY)
Growth
-100.0% -87.2% Higher Growth LYRA
Operating Margin (TTM)
Profitability
0.0% -25032.0% Higher Margin ENTX
Net Profit Margin
Profitability
0.0% 0.0% Higher Margin Tie
Return on Equity (ROE)
Capital Efficiency
-20.3% -404.5% Higher ROE ENTX
52-Week Range Position
Momentum
64% ($1–$4) 1% ($0–$38) Stronger Trend ENTX
Beta / 30D Volatility
Risk Regime
1.07β · 45% Vol 0.33β · 248% Vol Lower Realized Risk ENTX
Unified Institutional Score
Composite Signal
53.5 / 100 (HOLD) 52.2 / 100 (HOLD) Higher Composite ENTX
Trailing 12M Revenue (USD)
Operating Scale
N/A $600,000 FX-Normalized USD Scale
Gross Profit Margin (TTM)
Unit Pricing Power
N/A N/A Higher Margin Quality
PEG Ratio & EV / Revenue
Growth-Adjusted Valuation
N/M PEG · N/M EV/Rev N/M PEG · 3.9x EV/Rev Lower Multiple Valuation
Cash Flow & Balance Sheet
Capital Self-Funding
-$16M ($265M Net Cash) -$32M EBITDA (-404.5% ROE) Higher Cash / Net Cash Solvency

Momentum Normalized Relative Price Performance (1M · 3M · 6M · 1Y)

1M Horizon ENTX +51.32 pp
ENTX: -11.18% · LYRA: -62.5%
3M Horizon ENTX +48.71 pp
ENTX: -38.91% · LYRA: -87.62%
6M Horizon ENTX +36.96 pp
ENTX: -50.18% · LYRA: -87.14%
1Y Horizon ENTX +36.96 pp
ENTX: -50.18% · LYRA: -87.14%

Financial Trajectory Multi-Year Annual Revenue & Operating Margin Trajectory (USD)

Split-Invariant USD Revenue & Operating Margin (%)
Period ENTX Revenue LYRA Revenue ENTX Op. Margin LYRA Op. Margin Margin Leader
FY2020 $0M N/A -3059.7% N/A ENTX
FY2021 $0M $0M -2139.6% -15303.5% ENTX
FY2022 $0M $0M -9714.2% -4131.0% LYRA
FY2023 N/A $0M N/A -4308.1% LYRA
FY2024 $0M $0M -5295.6% -6280.8% ENTX
FY2025 $0M $0M -27450.0% -7794.5% LYRA

Options Positioning Implied Volatility, Put/Call Skew & Dealer Gamma Corridor

Live Options Phase Tracker
ENTX CONSOLIDATION
80d in phase · OBV NEUTRAL
Current IV 113.8%
IV Percentile 32nd %ile
Put/Call OI Skew N/A
IV Regime Balanced (25th–60th %ile)
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal BULLISH
OBV Flow NEUTRAL
Exact ENTX Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →
LYRA UNCLASSIFIED
0d in phase · OBV NEUTRAL
Current IV N/A
IV Percentile N/A
Put/Call OI Skew N/A
IV Regime Unclassified
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal NEUTRAL
OBV Flow NEUTRAL
Exact LYRA Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →

Moat & R&D Supply-Chain Positioning, Bottleneck Moat & R&D Velocity

Corporate R&D & Foundry Leaderboard
ENTX Moat Profile Cyclical / Execution-Driven Positioning
Biotechnology Operator
Competes within the Biotechnology value chain with $541.6M market capitalization and 0.0% operating margin.
OpEx & R&D Reinvestment N/A
90D Engineering Disclosures 0 Published
LYRA Moat Profile Cyclical / Execution-Driven Positioning
Biotechnology Operator
Competes within the Biotechnology value chain with $2.3M market capitalization and -25032.0% operating margin.
OpEx & R&D Reinvestment N/A
90D Engineering Disclosures 0 Published

Investor FAQ ENTX vs LYRA Key Questions & Quantitative Answers

As of Nov 17, 2026, Entera Bio Ltd. (ENTX) is the stronger overall head-to-head candidate over Lyra Therapeutics, Inc. (LYRA) in the Tradestie Institutional Equity Comparison Engine, winning 6–1 core matrix metrics and 3–2 across our 6-pillar institutional scorecard (led by Profitability & Quality, Balance Sheet & Cash Flow, Options & Positioning). ENTX carries a Unified Composite Score of 53.5/100 (HOLD) at $3.01 (N/M Forward P/E, 0.0% operating margin), whereas LYRA carries 52.2/100 (HOLD) at $0.49 (N/M Forward P/E, -25032.0% operating margin). Technical & Structure Timing Caution: ENTX trades in a Neutral technical trend (CONSOLIDATION options phase, RSI 49.8); meanwhile LYRA is in a short-term Weinstein Markdown pullback below its falling 50-day moving average (RSI 21.5). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.

LYRA leads the Growth & Scale pillar: ENTX posts -100.0% YoY revenue growth and +0.0% YoY earnings growth on N/A TTM revenue (N/A gross margin, 0.0% operating margin), compared with LYRA at -87.2% YoY revenue growth and +0.0% YoY earnings growth on $600,000 TTM revenue (N/A gross margin, -25032.0% operating margin). Across the 6-period historical trajectory (FY2020 to FY2025), ENTX cumulative revenue shifted N/A while LYRA shifted N/A. In operating R&D and SG&A reinvestment, ENTX deploys N/A (0 90-day corporate R&D disclosures) versus N/A (0 disclosures) for LYRA.

LYRA screens cheaper on headline valuation multiples. ENTX trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and N/M EV/Revenue (unreported FCF margin), whereas LYRA trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and 3.9x EV/Revenue (unreported EBITDA margin). Multiples above 150x or negative earnings denominators are marked N/M to avoid distorted accounting comparisons; weigh lower Forward P/E and PEG against ENTX (-20.3% ROE) versus LYRA (-404.5% ROE) capital efficiency.

In options market volatility and institutional positioning, ENTX carries 113.8% implied volatility (32nd %ile, Balanced (25th–60th %ile)), unclassified Put/Call open interest, NEUTRAL on-balance volume, and sits in a CONSOLIDATION options structure phase (1.07β · 45% Vol realized risk). By comparison, LYRA carries N/A implied volatility (N/A, Unclassified), unclassified Put/Call open interest, NEUTRAL on-balance volume, and sits in an UNCLASSIFIED options structure phase (0.33β · 248% Vol realized risk).

Cross-Compare 1-Click Peer Rivalries & Single-Stock Research

Launch Custom Ticker Comparison →

Powered by Tradestie Institutional Equity Comparison Engine & standardized corporate financial telemetry. Market close as of Nov 17, 2026. For educational research only; not investment advice.